Press

Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Mar 20 • 2 min read

Psyence Biomedical Ltd. issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably more therapeutic than synthetic psilocybin. Published on February 20, 2024, in the journal Molecular Psychiatry, the study was conducted by a research team from Hebrew University, and supervised by Professor Bernard Lerer, MD, Executive…

Filament Health Announces Shipments of Botanical Psilocybin to Four Countries for Clinical Investigation

Mar 19 • 3 min read

VANCOUVER, BC, March 19, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for…

Breakthrough in Wellness: Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China

Mar 19 • 3 min read

Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has been granted divisional patent approval by the China National Intellectual Property Administration. The divisional patent approval, previously…

Red Light Holland Announces Happy Caps Mushroom Home Grow Kits Now Available in Over 270 Retail Stores Across Canada

Mar 18 • 3 min read

Toronto, Ontario–(Newsfile Corp. – March 18, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the…

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Mar 18 • 2 min read

SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435